Beyond the Genome: Can Epigenetics Forecast Therapeutic Success in Graves’ Disease and Thyroid Eye Disease?
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27021116 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Jacopo Manso und 10 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology Unit, Oncology Area Department, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), 33100 Udine, Italy. Hauptthemen laut MEDLINE: Graves Disease, Graves Ophthalmopathy, Epigenesis, Genetic. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Graves’ disease (GD) and Thyroid Eye Disease (TED) are autoimmune disorders characterized by significant heterogeneity in treatment response. Up to 50% of GD patients relapse after antithyroid drug (ATD) withdrawal, and a substantial portion of TED patients (20–50%) are resistant to first-line glucocorticoid (GC) therapy. This review evaluates the current evidence on epigenetic modifications as predictive biomarkers to guide personalized treatment. We synthesized recent findings (up to 2025) from PubMed, focusing on DNA methylation and microRNAs (miRNAs). For GD, ATD relapse risk is linked to a persistent “epigenetic memory” in T cells, notably the hypomethylation of Th17-associated genes. Circulating miRNA signatures, including miR-346, miR-23b-5p, and miR-92a-3p, also show promise in predicting remission. For TED, GC sensitivity is strongly correlated with specific circulating miRNAs. High pre-treatment levels of miR-146a predict a positive response (100% positive predictive value), while low levels of miR-224-5p predict non-responsiveness. While DNA methylation is confirmed in TED pathogenesis, its predictive role is unstudied. Major research gaps persist, particularly the near-total absence of data on histone modifications as predictive markers and the lack of epigenetic predictors for new biologics treatments, which currently rely on genetic or pharmacokinetic markers. Epigenetic biomarkers represent a promising frontier for stratifying patients and optimizing therapeutic strategies in Graves’ autoimmunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Endocrinology Unit, Oncology Area Department, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), 33100 Udine, Italy.
- Department of Medical Surgical and Health Sciences, Cattinara Teaching Hospital, University of Trieste, Strada di Fiume 447, 34149 Trieste, Italy.
- Department of Medicine, Surgery and Dentistry, "Scuola Medica Salernitana", University of Salerno, 84084 Baronissi, Italy.
ORCID-Profile: Jacopo Manso, Dario Sardone, Vincenzo Marotta, Antonio Stefano Salcuni, Maria Carpentieri, Alberto Falchetti, Fabio Vescini
Zitieren
APA
Manso, J., Sardone, D., Marotta, V., Salcuni, A. S., Brunetti, A., Cipri, C., Sciannimanico, S. M., Piva, L., Carpentieri, M., Falchetti, A., & Vescini, F. (2026). Beyond the Genome: Can Epigenetics Forecast Therapeutic Success in Graves’ Disease and Thyroid Eye Disease?. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27021116
Vancouver
Manso J, Sardone D, Marotta V, Salcuni AS, Brunetti A, Cipri C, et al. Beyond the Genome: Can Epigenetics Forecast Therapeutic Success in Graves’ Disease and Thyroid Eye Disease?. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27021116
BibTeX
@article{Manso2026,
author = {Manso, Jacopo and Sardone, Dario and Marotta, Vincenzo and Salcuni, Antonio Stefano and Brunetti, Alessandro and Cipri, Claudia and Sciannimanico, Silvia Maria and Piva, Lorenzo and Carpentieri, Maria and Falchetti, Alberto and Vescini, Fabio},
title = {Beyond the Genome: Can Epigenetics Forecast Therapeutic Success in Graves’ Disease and Thyroid Eye Disease?},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27021116}
}
EUVIMED